Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The Company focuses on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anti-cancer quinolone derivative (AQD). Vosaroxin has been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company licensed development and commercialization rights to vosaroxin from Dainippon Sumitomo Pharma Co., Ltd. The Company does not have internal manufacturing capabilities for the production of clinical or commercial quantities of vosaroxin.